When the SAFE Drugs Act was first introduced, we viewed it as uniquely threatening to the On The Pen community. While much of the initial conversation surrounding this bill centered on pharmacy regulation and FDA authority, our concern was much more straightforward. We believed portions of the legislation, however well-intentioned, risked disrupting patient access to compounded medications during legitimate drug shortages. That concern prompted us to launch one of the earliest public campaigns opposing the bill, not because we oppose regulation, but because we believed lawmakers deserved to hear directly from the patients whose lives could be affected.
More than 5,700 people ultimately signed our Change.org petition, making it the largest organized patient response to the legislation. Those signatures came from patients living with obesity and diabetes, physicians, pharmacists, caregivers, and advocates who shared a common concern that Congress should not unintentionally eliminate an important pathway for maintaining treatment continuity during FDA-recognized shortages. While we cannot be certain as to how much our fight affected the changes to this piece of federal legislation, public advocacy serves an important purpose. It demonstrates to policymakers that people outside Washington are paying attention, and it gives elected officials a clearer understanding of how proposed legislation may affect the people they represent. Together, we were a part of that, and our advocacy appears to have mattered.
ON THE PEN is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
The Senate HELP Committee adopted a manager’s amendment that substantially revises the SAFE Drugs Act. According to the Alliance for Pharmacy Compounding, the amended legislation removes language that would have dramatically restricted shortage-drug compounding while preserving pharmacies’ ability to continue helping patients receive medication when FDA-approved products are unavailable because of shortages. The organization also praised the addition of mandatory serious adverse event reporting through FDA’s existing reporting systems, describing the revised legislation as a “vast improvement” over the bill as originally introduced. After reviewing the amendment and APC’s assessment, we agree.
The removal of the shortage-drug language represents the most significant policy change in the legislation to date. Under the original proposal, many pharmacy organizations feared that the bill could effectively dismantle long-standing mechanisms allowing compounded medications to fill temporary gaps in the nation’s drug supply. For patients who endured years of GLP-1 shortages, that was never an abstract regulatory question. It was a question about whether treatment could continue when commercially manufactured medications simply were not available. By preserving the existing shortage framework, lawmakers appear to have recognized that protecting patients sometimes requires balancing regulatory oversight with practical realities inside the healthcare system.
The revised legislation also strengthens patient safety by requiring mandatory reporting of serious adverse events through FDA’s existing reporting infrastructure. That provision deserves broad support because meaningful oversight depends upon accurate safety data. Responsible compounders have every incentive to identify bad actors operating outside accepted standards, and regulators benefit when they receive more complete information regarding serious complications. Patient safety and patient access have never been mutually exclusive goals, and legislation should reflect both priorities simultaneously.
One of the more fascinating developments throughout this debate has been the political consensus surrounding access to GLP-1 medications. Over the past several months, I have spoken with political operatives and policy advisors on both sides of the aisle, and one theme has emerged repeatedly. Access to obesity medications has quietly become one of the most bipartisan healthcare issues in America. Republicans often emphasize the long-term economic benefits of reducing chronic disease, increasing workforce participation, and lowering healthcare spending. Democrats frequently focus on expanding access to effective treatment, preventive medicine, and improving health equity. And no matter where someone falls politically, we all know someone who has had to deal with the consequences of this awful disease. This serves as a huge encouragement for this advocate.
That political reality makes this legislative outcome especially worthy of our continued attention. Congress rarely changes course unless lawmakers believe constituents are paying attention. The Alliance for Pharmacy Compounding deserves considerable credit for working directly with Senate staff to improve the bill’s technical language. At the same time, thousands of patients in our community took the time to sign the petition, contact elected officials, share personal stories, and explain why continuity of care matters. Legislative outcomes are almost always the product of many voices working toward the same objective, and this appears to be another example of that process functioning as intended.
The legislation is not finished, nor is the work surrounding it. APC continues to express concerns regarding the interstate dispensing reporting provision, arguing that portions of the language may conflict with existing law. Those issues will continue to be debated as the bill advances toward consideration by the full Senate, and additional amendments remain possible before any legislation reaches the President’s desk. We will continue following those developments closely because the details of healthcare policy often determine whether patients experience continuity of care or unnecessary barriers to treatment.
For now, however, last week’s amendment represents something worth recognizing. The SAFE Drugs Act that emerged from committee is materially different from the bill that was introduced months ago. Whether those changes resulted from pharmacists, physicians, patient advocates, professional organizations, or thousands of individuals who took the time to make their voices heard is ultimately less important than the broader lesson. Advocacy works best when it remains focused on patients, and this week’s developments suggest that Washington was willing to listen.
